New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
07:47 EDTDVAXDynavax a compelling buy at current levels, says Jefferies
Jefferies views Dynavax as a risky but compelling buy at current levels following the negative FDA panel vote on the company's hepatitis B vaccine. The firm lowered its price target for shares to $5 from $5 and keeps a Buy rating on the stock.
News For DVAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 23, 2015
10:00 EDTDVAXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:23 EDTDVAXDynavax upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Dynavax to Overweight saying it is now "significantly more comfortable" with the safety of the company's Heplisav vaccine for hepatitis B. The firm raised its price target for shares to $36 from $15.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use